- Home
- NEPH vs AEON Comparison
NEPH vs AEON Comparison
Compare NEPH & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEPH | AEON |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 26.8M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEPH | AEON |
|---|---|---|
| Price | $2.88 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $7.20 |
| AVG Volume (30 Days) | 46.3K | ★ 67.4K |
| Earning Date | 03-12-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1000.00 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $18,789,000.00 | N/A |
| Revenue This Year | $12.82 | N/A |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $26.91 | ★ N/A |
| Revenue Growth | ★ 32.67 | N/A |
| 52 Week Low | $1.51 | $0.38 |
| 52 Week High | $6.42 | $1.45 |
Technical Indicators
Market Signals| Indicator | NEPH | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 29.42 | 51.94 |
| Support Level | N/A | $0.69 |
| Resistance Level | $4.93 | $1.42 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 5.24 | 58.88 |
Price Performance
Historical ComparisonAbout NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.